37465997|t|Fractalkine Enhances Hematoma Resolution and Improves Neurological Function via CX3CR1/AMPK/PPARgamma Pathway After GMH.
37465997|a|BACKGROUND: Hematoma clearance has been a proposed therapeutic strategy for hemorrhagic stroke. This study investigated the impact of CX3CR1 (CX3C chemokine receptor 1) activation mediated by r-FKN (recombinant fractalkine) on hematoma resolution, neuroinflammation, and the underlying mechanisms involving AMPK (AMP-activated protein kinase)/PPARgamma (peroxisome proliferator-activated receptor gamma) pathway after experimental germinal matrix hemorrhage (GMH). METHODS: A total of 313 postnatal day 7 Sprague Dawley rat pups were used. GMH was induced using bacterial collagenase by a stereotactically guided infusion. r-FKN was administered intranasally at 1, 25, and 49 hours after GMH for short-term neurological evaluation. Long-term neurobehavioral tests (water maze, rotarod, and foot-fault test) were performed 24 to 28 days after GMH with the treatment of r-FKN once daily for 7 days. To elucidate the underlying mechanism, CX3CR1 CRISPR, or selective CX3CR1 inhibitor AZD8797, was administered intracerebroventricularly 24 hours preinduction of GMH. Selective inhibition of AMPK/PPARgamma signaling in microglia via intracerebroventricularly delivery of liposome-encapsulated specific AMPK (Lipo-Dorsomorphin), PPARgamma (Lipo-GW9662) inhibitor. Western blot, Immunofluorescence staining, Nissl staining, Hemoglobin assay, and ELISA assay were performed. RESULTS: The brain expression of FKN and CX3CR1 were elevated after GMH. FKN was expressed on both neurons and microglia, whereas CX3CR1 was mainly expressed on microglia after GMH. Intranasal administration of r-FKN improved the short- and long-term neurobehavioral deficits and promoted M2 microglia polarization, thereby attenuating neuroinflammation and enhancing hematoma clearance, which was accompanied by an increased ratio of p-AMPK (phosphorylation of AMPK)/AMPK, Nrf2 (nuclear factor erythroid 2-related factor 2), PPARgamma, CD36 (cluster of differentiation 36), CD163 (hemoglobin scavenger receptor), CD206 (the mannose receptor), and IL (interleukin)-10 expression, and decreased CD68 (cluster of differentiation 68), IL-1beta, and TNF (tumor necrosis factor) alpha expression. The administration of CX3CR1 CRISPR or CX3CR1 inhibitor (AZD8797) abolished the protective effect of FKN. Furthermore, selective inhibition of microglial AMPK/PPARgamma signaling abrogated the anti-inflammation effects of r-FKN after GMH. CONCLUSIONS: CX3CR1 activation by r-FKN promoted hematoma resolution, attenuated neuroinflammation, and neurological deficits partially through the AMPK/PPARgamma signaling pathway, which promoted M1/M2 microglial polarization. Activating CX3CR1 by r-FKN may provide a promising therapeutic approach for treating patients with GMH.
37465997	0	11	Fractalkine	Gene	89808
37465997	21	29	Hematoma	Disease	MESH:D006406
37465997	80	86	CX3CR1	Gene	171056
37465997	87	91	AMPK	Gene	78975
37465997	92	101	PPARgamma	Gene	25664
37465997	116	119	GMH	Disease	MESH:D054331
37465997	133	141	Hematoma	Disease	MESH:D006406
37465997	197	215	hemorrhagic stroke	Disease	MESH:D000083302
37465997	255	261	CX3CR1	Gene	171056
37465997	263	288	CX3C chemokine receptor 1	Gene	171056
37465997	313	318	r-FKN	Chemical	-
37465997	332	343	fractalkine	Gene	89808
37465997	348	356	hematoma	Disease	MESH:D006406
37465997	369	386	neuroinflammation	Disease	MESH:D000090862
37465997	428	432	AMPK	Gene	78975
37465997	434	462	AMP-activated protein kinase	Gene	78975
37465997	464	473	PPARgamma	Gene	25664
37465997	475	523	peroxisome proliferator-activated receptor gamma	Gene	25664
37465997	552	578	germinal matrix hemorrhage	Disease	MESH:D054331
37465997	580	583	GMH	Disease	MESH:D054331
37465997	661	664	GMH	Disease	MESH:D054331
37465997	744	749	r-FKN	Chemical	-
37465997	809	812	GMH	Disease	MESH:D054331
37465997	911	921	foot-fault	Disease	MESH:D005530
37465997	963	966	GMH	Disease	MESH:D054331
37465997	989	994	r-FKN	Chemical	-
37465997	1057	1063	CX3CR1	Gene	171056
37465997	1085	1091	CX3CR1	Gene	171056
37465997	1102	1109	AZD8797	Chemical	MESH:C000609791
37465997	1179	1182	GMH	Disease	MESH:D054331
37465997	1208	1212	AMPK	Gene	78975
37465997	1213	1222	PPARgamma	Gene	25664
37465997	1319	1323	AMPK	Gene	78975
37465997	1325	1342	Lipo-Dorsomorphin	Chemical	-
37465997	1345	1354	PPARgamma	Gene	25664
37465997	1356	1367	Lipo-GW9662	Chemical	-
37465997	1530	1536	CX3CR1	Gene	171056
37465997	1557	1560	GMH	Disease	MESH:D054331
37465997	1619	1625	CX3CR1	Gene	171056
37465997	1666	1669	GMH	Disease	MESH:D054331
37465997	1700	1705	r-FKN	Chemical	-
37465997	1740	1764	neurobehavioral deficits	Disease	MESH:D019954
37465997	1825	1842	neuroinflammation	Disease	MESH:D000090862
37465997	1857	1865	hematoma	Disease	MESH:D006406
37465997	1926	1930	AMPK	Gene	78975
37465997	1951	1955	AMPK	Gene	78975
37465997	1957	1961	AMPK	Gene	78975
37465997	1963	1967	Nrf2	Gene	83619
37465997	1969	2012	nuclear factor erythroid 2-related factor 2	Gene	83619
37465997	2015	2024	PPARgamma	Gene	25664
37465997	2064	2069	CD163	Gene	312701
37465997	2137	2156	IL (interleukin)-10	Gene	25325
37465997	2221	2229	IL-1beta	Gene	3553
37465997	2235	2238	TNF	Gene	7124
37465997	2240	2268	tumor necrosis factor) alpha	Gene	7124
37465997	2303	2309	CX3CR1	Gene	1524
37465997	2320	2326	CX3CR1	Gene	1524
37465997	2338	2345	AZD8797	Chemical	MESH:C000609791
37465997	2382	2385	FKN	Chemical	-
37465997	2435	2439	AMPK	Gene	5564
37465997	2440	2449	PPARgamma	Gene	5468
37465997	2479	2491	inflammation	Disease	MESH:D007249
37465997	2503	2508	r-FKN	Chemical	-
37465997	2515	2518	GMH	Disease	MESH:D054331
37465997	2533	2539	CX3CR1	Gene	1524
37465997	2554	2559	r-FKN	Chemical	-
37465997	2569	2577	hematoma	Disease	MESH:D006406
37465997	2601	2618	neuroinflammation	Disease	MESH:D000090862
37465997	2624	2645	neurological deficits	Disease	MESH:D009461
37465997	2668	2672	AMPK	Gene	5564
37465997	2673	2682	PPARgamma	Gene	5468
37465997	2759	2765	CX3CR1	Gene	1524
37465997	2769	2774	r-FKN	Chemical	-
37465997	2847	2850	GMH	Disease	MESH:D054331
37465997	Association	MESH:D054331	3553
37465997	Association	25664	78975
37465997	Association	MESH:D054331	25664
37465997	Association	5468	5564
37465997	Association	MESH:D006406	7124
37465997	Negative_Correlation	1524	5564
37465997	Association	78975	89808
37465997	Association	171056	89808
37465997	Association	MESH:D054331	171056
37465997	Association	MESH:D054331	7124
37465997	Association	MESH:D006406	78975
37465997	Association	MESH:D019954	78975
37465997	Association	MESH:D000090862	83619
37465997	Association	MESH:D054331	78975
37465997	Association	MESH:D000090862	25325
37465997	Association	MESH:C000609791	MESH:D054331
37465997	Association	MESH:D054331	25325
37465997	Association	MESH:D000090862	78975
37465997	Association	MESH:D006406	89808
37465997	Association	MESH:D007249	5468
37465997	Association	25664	89808
37465997	Association	MESH:D054331	89808
37465997	Association	MESH:D006406	25325
37465997	Association	MESH:D006406	312701
37465997	Association	MESH:D054331	83619
37465997	Negative_Correlation	1524	5468
37465997	Association	MESH:D006406	171056
37465997	Association	MESH:D019954	25664
37465997	Association	MESH:D006406	83619
37465997	Negative_Correlation	MESH:C000609791	171056
37465997	Association	MESH:D006406	25664
37465997	Association	MESH:D009461	5468
37465997	Association	MESH:D000090862	25664
37465997	Association	MESH:D009461	5564
37465997	Association	MESH:D006406	3553

